Literature DB >> 17472989

Autoantibodies binding to citrullinated telopeptide of type II collagen and to cyclic citrullinated peptides predict synergistically the development of seropositive rheumatoid arthritis.

Marja-Kaisa Koivula1, Markku Heliövaara, Jarmo Ramberg, Paul Knekt, Harri Rissanen, Timo Palosuo, Juha Risteli.   

Abstract

OBJECTIVES: To find out whether autoantibodies to citrullinated telopeptides of type I and II collagens and to cyclic citrullinated peptides (CCPs) predict the development of rheumatoid arthritis (RA).
METHODS: A case-control study (matched for sex, age and municipality) was nested within a Finnish cohort of 19072 adults who had neither arthritis nor a history of it at the baseline examination during 1973-7. 124 subjects developed RA by late 1989, and of these, 89 were positive for rheumatoid factor (RF). Preillness serum specimens were analysed for autoantibodies against arginine (A)- or citrulline (C)-containing synthetic telopeptides using a chemiluminescence method and for anti-CCPs Mark2 with an enzyme-linked immunosorbent assay method.
RESULTS: The mean levels of autoantibodies to citrulline-containing telopeptides and the C/A ratios of type I and II collagens and to CCP were higher in subjects who later developed RF-positive RA. In the highest tertiles of C/A (I), C/A (II) ratios and anti-CCPs levels, the relative risk of RF-positive RA was significantly increased. In the multifactorial model, only anti-CCPs retained its statistical significance. However, the interaction term of C/A (II) ratio and anti-CCPs proved to be statistically significant (p = 0.02). The subjects ranked into the highest tertiles of both C/A (II) ratio and anti-CCPs had an odds ratio of 20.06 (95% confidence interval, 4.37 to 92.06) of developing RF-positive RA compared with those in the lowest tertiles of these antibodies. None of the autoantibodies predicted RF-negative RA.
CONCLUSION: Autoantibodies to citrullinated telopeptides of type I and II collagen and to CCPs exert a synergistic effect on the risk of seropositive RA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17472989      PMCID: PMC2111613          DOI: 10.1136/ard.2006.062919

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  41 in total

1.  Clinical trials. Diabetes' brave new world.

Authors:  Jennifer Couzin
Journal:  Science       Date:  2003-06-20       Impact factor: 47.728

2.  Pathogenic role of antibodies to citrullinated proteins in rheumatoid arthritis.

Authors:  Andrew J Kinloch; Karin E Lundberg; David Moyes; Patrick J Venables
Journal:  Expert Rev Clin Immunol       Date:  2006-05       Impact factor: 4.473

3.  The enzymic derivation of citrulline residues from arginine residues in situ during the biosynthesis of hair proteins that are cross-linked by isopeptide bonds.

Authors:  G E Rogers; L D Taylor
Journal:  Adv Exp Med Biol       Date:  1977       Impact factor: 2.622

4.  Anti-citrullinated collagen type I antibody is a target of autoimmunity in rheumatoid arthritis.

Authors:  Akari Suzuki; Ryo Yamada; Miyako Ohtake-Yamanaka; Yuko Okazaki; Tetsuji Sawada; Kazuhiko Yamamoto
Journal:  Biochem Biophys Res Commun       Date:  2005-07-29       Impact factor: 3.575

5.  Incidence of rheumatoid arthritis in Finland during 1980-1990.

Authors:  O Kaipiainen-Seppänen; K Aho; H Isomäki; M Laakso
Journal:  Ann Rheum Dis       Date:  1996-09       Impact factor: 19.103

Review 6.  Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review.

Authors:  J Avouac; L Gossec; M Dougados
Journal:  Ann Rheum Dis       Date:  2006-04-10       Impact factor: 19.103

7.  The Social Insurance Institution's coronary heart disease study. Baseline data and 5-year mortality experience.

Authors:  A Reunanen; A Aromaa; K Pyörälä; S Punsar; J Maatela; P Knekt
Journal:  Acta Med Scand Suppl       Date:  1983

8.  Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process.

Authors:  K Aho; R von Essen; P Kurki; T Palosuo; M Heliövaara
Journal:  J Rheumatol       Date:  1993-08       Impact factor: 4.666

9.  When does rheumatoid disease start?

Authors:  K Aho; T Palosuo; V Raunio; P Puska; A Aromaa; J T Salonen
Journal:  Arthritis Rheum       Date:  1985-05

10.  Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages.

Authors:  E R Vossenaar; T R D Radstake; A van der Heijden; M A M van Mansum; C Dieteren; D-J de Rooij; P Barrera; A J W Zendman; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  2004-04       Impact factor: 19.103

View more
  7 in total

Review 1.  The influence of ACPA status and characteristics on the course of RA.

Authors:  Annemiek Willemze; Leendert A Trouw; René E M Toes; Tom W J Huizinga
Journal:  Nat Rev Rheumatol       Date:  2012-01-31       Impact factor: 20.543

Review 2.  Possible roles of anti-type II collagen antibody and innate immunity in the development and progression of diabetic retinopathy.

Authors:  Tsunehiko Ikeda; Kimitoshi Nakamura; Teruyo Kida; Hidehiro Oku
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-08-11       Impact factor: 3.535

3.  Relatives without rheumatoid arthritis show reactivity to anti-citrullinated protein/peptide antibodies that are associated with arthritis-related traits: studies of the etiology of rheumatoid arthritis.

Authors:  Kendra A Young; Kevin D Deane; Lezlie A Derber; Jan M Hughes-Austin; Catriona A Wagner; Jeremy Sokolove; Michael H Weisman; Jane H Buckner; Ted R Mikuls; James R O'Dell; Richard M Keating; Peter K Gregersen; William H Robinson; V Michael Holers; Jill M Norris
Journal:  Arthritis Rheum       Date:  2013-08

4.  Reactive oxygen species deficiency induces autoimmunity with type 1 interferon signature.

Authors:  Tiina Kelkka; Deborah Kienhöfer; Markus Hoffmann; Marjo Linja; Kajsa Wing; Outi Sareila; Malin Hultqvist; Essi Laajala; Zhi Chen; Júlia Vasconcelos; Esmeralda Neves; Margarida Guedes; Laura Marques; Gerhard Krönke; Merja Helminen; Leena Kainulainen; Peter Olofsson; Sirpa Jalkanen; Riitta Lahesmaa; M Margarida Souto-Carneiro; Rikard Holmdahl
Journal:  Antioxid Redox Signal       Date:  2014-07-29       Impact factor: 8.401

5.  Separate and overlapping specificities in rheumatoid arthritis antibodies binding to citrulline- and homocitrulline-containing peptides related to type I and II collagen telopeptides.

Authors:  Sanna Turunen; Pekka Hannonen; Marja-Kaisa Koivula; Leila Risteli; Juha Risteli
Journal:  Arthritis Res Ther       Date:  2015-01-09       Impact factor: 5.156

Review 6.  Engineered T cells and their therapeutic applications in autoimmune diseases.

Authors:  Lei Bao; Xiao-Chen Bo; Huai-Wen Cao; Chen Qian; Zeng Wang; Bin Li
Journal:  Zool Res       Date:  2022-03-18

7.  Different amounts of protein-bound citrulline and homocitrulline in foot joint tissues of a patient with anti-citrullinated protein antibody positive erosive rheumatoid arthritis.

Authors:  Sanna Turunen; Marja-Kaisa Koivula; Jukka Melkko; Eeva Alasaarela; Petri Lehenkari; Juha Risteli
Journal:  J Transl Med       Date:  2013-09-23       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.